

## **FULCRUM PHARMA PLC**

("Fulcrum" or "the Group" or "the Company")

### **Significant Service Contract signed with Celtic Pharma**

Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcing services company, is pleased to announce the signing of a significant three-year agreement with Celtic Pharma Development Services Bermuda Ltd. ("Celtic"). Under the terms of this agreement Fulcrum will provide drug development services to Celtic in Europe, US and Japan.

Celtic is a leading global private equity firm focused on pharmaceutical and biotechnology products. Celtic builds value in differentiated and commercially attractive pharmaceutical products by driving them through the final stages of the drug approval process, employing a rigorous "virtual pharma" model of drug development. Fulcrum has a proven record in developing new drugs efficiently and cost effectively using its global, virtual, drug development services model. Fulcrum's services offer an excellent strategic fit with Celtic and Fulcrum is well placed to contribute to Celtic's success.

Initially Fulcrum will be leveraging its virtual model to support the development of four of Celtic's late stage clinical programmes, specifically the brain cancer treatment TransMID, the two anti-addiction vaccines, TA-CD and TA-NIC, plus, outside of the USA, the treatment for brain oedema, Xerecept.

**Jon Court, CEO, of Fulcrum Pharma, commented:** "Our management team is delighted to become a drug development partner with Celtic. Our company, being an originator of the virtual model, shares Celtic's enthusiasm for the effectiveness and efficiency of virtual development. This agreement strengthens Fulcrum and represents a further significant step in the development of Fulcrum's partnership strategy."

"Fulcrum has the experience, resources and quality to help us add value to our important therapeutic products," **said John Mayo, Joint General Managing Partner of Celtic Pharma.** "We look forward to a long and successful relationship with the Fulcrum team."

**Dr. Patrick O'Connor, Head of Clinical Development for Celtic Pharma Development Services, added:** "We see the Fulcrum team as an essential addition to our in-house resources as we look to leverage our team to deliver high quality development products to the regulatory authorities in the key markets. We are actively working with the Fulcrum team to ensure that the first four candidates move forward rapidly."

**FOR FURTHER INFORMATION, PLEASE CONTACT:**

**Fulcrum Pharma PLC**

Ashley Nagle, Business Development Director

**Tel: 0870 712 0538**

**Celtic Pharma**

Kathy Armstrong

**Tel: 212-616-4042**

**Financial Dynamics**

Matt Dallas

**Tel: 212-850-5627**

**Notes for editors**

**About Fulcrum Pharma plc**

Fulcrum Pharma plc is an independent, drug development company that offering global virtual drug development and strategic outsourcing services to the pharmaceutical industry. The Group is expert in the design, execution and delivery of drug development programmes and works with both emerging biotech / pharma companies as well larger Pharma companies.

Through Fulcrum Pharma's services to its clients, the Directors believe that there is the capacity to deliver products faster and more efficiently to the global pharmaceutical market. Fulcrum Pharma does this by using its skills in the design of drug programmes that deliver the necessary information for decision-making and product development. In so doing, Fulcrum Pharma works closely with its clients to meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London Stock Exchange having successfully floated in March 2000.

For further information please visit Fulcrum Pharma's website at [www.fulcrumpharma.com](http://www.fulcrumpharma.com)

**About Celtic Pharmaceutical Holdings L.P.**

Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) is a global private equity investment firm focused on the biotechnology and pharmaceutical industries. Celtic Pharma was founded by Stephen Evans-Freke and John Mayo, CBE and is based in Bermuda, with offices in New York and London. Celtic Pharma acquires and invests in late stage pharmaceutical programs and drives these programs through the final stages of regulatory approval. Celtic Pharma's aim is to bridge the gap between the established pharmaceutical companies' new product pipeline crisis and the biotech industry's capital drought.

For further information, please visit Celtic Pharma's website at [www.celticpharma.com](http://www.celticpharma.com)